IMGN News and Press, ImmunoGen Inc. From 10/29/21

ImmunoGen (NASDAQ:IMGN): Q3 GAAP EPS of -$0.18 in-line. Revenue of $9.21M (-49.4% Y/Y) misses by $9.82M. Shares +1.3% PM. Press Release ImmunoGen has updated its financial guidance for 2021 and now expects: Affirms revenue guidance between $65 million and $75 million; operating expenses betwe...

Top-Line Data from Pivotal SORAYA Trial Evaluating Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer on Track for Release this Quarter IMGN632 AML Combination Data to be Highlighted at ASH Annual Meeting PICCOLO, Single-Arm Study of Mirvetuximab in Platinu...

ImmunoGen (NASDAQ:IMGN) is scheduled to announce Q3 earnings results on Friday, October 29th, before market open. The consensus EPS Estimate is -$0.19 and the consensus Revenue Estimate is $19.03M (+4.6% Y/Y). Seeking Alpha contributor Avisol Capital Partners said that "ImmunoGen is a le...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 29, 2021 to discuss its third quarter operating results. Man...

The Covid story is starting to change. And you can hear the popping sound in the vaccine space. The needle is “therapeutics”. The therapeutic route was thought to be tricky for this virus on the near-term time horizon, which fueled a massive tsunami into the vaccine stocks as la...

ImmunoGen is a leader in antibody drug conjugate technology. The company has important catalysts ahead. Current lows make the stock interesting. For further details see: ImmunoGen: Important Catalysts Ahead

Piper Sandler Technical Market Strategist Craig. W. Johnson is out with his latest quarterly Alpha Alignment Report, which screens 900 stocks for a host of fundamental and technical factors. Along with the headline Alpha Alignment Index, the report also screens for an equal-weighted Short Squ...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray, MD, FAAP to its Board of Directors. "Helen joins ImmunoGen's Board of Directors at an exciting tim...

With the dominance of the giants in the Covid vaccine space, biotech stocks have outperformed the market this year by a wide margin. But almost all of that outperformance has been isolated in the large-cap factor zone in the space, leaving small-cap biotech players to badly lag the market. Th...

ImmunoGen, Inc. (IMGN) Q2 2021 Earnings Conference Call July 30, 2021, 08:00 ET Company Participants Courtney O’Konek - Senior Director, Corporate Communications & IR Mark Enyedy - President, CEO & Director Anna Berkenblit - SVP & Chief Medical Officer Susan Altschuller - S...